Monopar Therapeutics stock (US6093601054): Shares up 3% at $65.52

Monopar Therapeutics (MNPR) stock rose 3.06% to $65.52 USD amid ongoing clinical development in oncology. The Nasdaq-listed biopharma focuses on innovative cancer therapies targeting underserved patient populations.

Monopar Therapeutics stock advanced 3.06% to 65.520 USD on Nasdaq, according to TradingKey as of May 2026. The clinical-stage biopharmaceutical company specializes in developing novel treatments for cancer patients with limited options. This price move reflects investor interest in its pipeline progress.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Monopar Therapeutics Inc
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: United States
• Core markets: US, global clinical trials
• Key revenue drivers: Pipeline milestones, partnerships
• Home exchange/listing venue: Nasdaq (MNPR)
• Trading currency: USD

Monopar Therapeutics: core business model

Monopar Therapeutics is a clinical-stage biopharma company dedicated to advancing targeted radiopharma and oncology therapeutics. Its lead candidates include MNPR-101, a humanized monoclonal antibody targeting the uPAR receptor overexpressed in aggressive solid tumors, and MNPR-201, a novel chelator for radiopharmaceuticals. The company aims to address unmet needs in cancers like pancreatic and ovarian tumors through precision medicine approaches, as detailed on its IR site as of May 2026.

Monopar's strategy emphasizes efficient development with a lean team, leveraging partnerships for manufacturing and clinical execution. This model minimizes cash burn while advancing programs toward key milestones such as IND filings and Phase 1 data readouts, positioning it for potential licensing deals or buyouts common in biotech.

Main revenue and product drivers for Monopar Therapeutics

Pipeline progression drives value for Monopar Therapeutics, with MNPR-101 in preclinical stages showing promising tumor penetration data. The company is preparing for first-in-human trials, which could catalyze stock moves. MNPR-201 supports alpha-emitting radiopharma applications, tapping into the growing $10B+ market projected by 2030 per sector reports.

Future revenues hinge on clinical milestones, regulatory clearances, and partnerships. Nasdaq listing provides visibility to US investors, with exposure to the booming oncology sector amid rising cancer incidence in the US.

Industry trends and competitive position

The radiopharma space is heating up, with players like Novartis and AstraZeneca investing billions. Monopar differentiates via its uPAR-targeting approach, potentially enabling better delivery to hypoxic tumors resistant to standard therapies. US investors benefit from Nasdaq access and FDA pathway familiarity.

Conclusion

Monopar Therapeutics continues to advance its oncology pipeline amid a recent 3% share price gain to $65.52 on Nasdaq. With focused programs in radiopharma and targeted antibodies, the company targets high-unmet-need cancers. Investors track upcoming clinical milestones, though biotech risks remain inherent. US market exposure enhances relevance for domestic portfolios.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.